These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25367314)

  • 41. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
    Teerawattananon Y; Mugford M; Tangcharoensathien V
    Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Catheter-based radiofrequency renal sympathetic denervation for resistant hypertension.
    Damascelli B; Patelli G; Tichá V; Della Rocca F; Lattuada S; Sala C; Albertoni A; D'Alessio A; Funaro A; Scotti L
    J Vasc Interv Radiol; 2013 May; 24(5):632-9. PubMed ID: 23622036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of catheter-based radiofrequency renal denervation in stented renal arteries.
    Mahfoud F; Tunev S; Ruwart J; Schulz-Jander D; Cremers B; Linz D; Zeller T; Bhatt DL; Rocha-Singh K; Böhm M; Melder RJ
    Circ Cardiovasc Interv; 2014 Dec; 7(6):813-20. PubMed ID: 25336466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting.
    Zhang Y; Kivipelto M; Solomon A; Wimo A
    J Alzheimers Dis; 2011; 26(4):735-44. PubMed ID: 21709377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
    Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
    Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Renal Denervation for Resistant Hypertension in the contemporary era: A Systematic Review and Meta-analysis.
    Agasthi P; Shipman J; Arsanjani R; Ashukem M; Girardo ME; Yerasi C; Venepally NR; Fortuin FD; Mookadam F
    Sci Rep; 2019 Apr; 9(1):6200. PubMed ID: 30996305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
    Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
    Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients.
    Hayek SS; Abdou MH; Demoss BD; Legaspi JM; Veledar E; Deka A; Krishnan SK; Wilmot KA; Patel AD; Kumar VR; Devireddy CM
    Am J Hypertens; 2013 Dec; 26(12):1452-8. PubMed ID: 23934709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension.
    Ukena C; Mahfoud F; Spies A; Kindermann I; Linz D; Cremers B; Laufs U; Neuberger HR; Böhm M
    Int J Cardiol; 2013 Sep; 167(6):2846-51. PubMed ID: 22917547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal Denervation in Patients with Resistant Hypertension-Assessment by 3T Renal 23Na-MRI: Preliminary Results.
    Budjan J; Benck U; Lammert A; Ong MM; Mircheva M; Diehl S; Konstandin S; Schad LR; Krämer BK; Schoenberg SO; Haneder S
    In Vivo; 2016 09-10; 30(5):657-62. PubMed ID: 27566087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension.
    Taylor RS; Bentley A; Metcalfe K; Lobo MD; Kirtane AJ; Azizi M; Clark C; Murphy K; Boer JH; van Keep M; Ta AT; Barman NC; Schwab G; Akehurst R; Schmieder RE
    Pharmacoecon Open; 2024 Jul; 8(4):525-537. PubMed ID: 38289517
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of milk powder fortified with potassium to decrease blood pressure and prevent cardiovascular events among the adult population in China: a Markov model.
    Dainelli L; Xu T; Li M; Zimmermann D; Fang H; Wu Y; Detzel P
    BMJ Open; 2017 Sep; 7(9):e017136. PubMed ID: 28951410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of renal denervation on resistant hypertension patients: a meta-analysis.
    Zhang X; Wu N; Yan W; Zhou C; Guo H
    Blood Press Monit; 2016 Aug; 21(4):206-14. PubMed ID: 26901340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is renal denervation an effective treatment for hypertension? Comparison of recent meta-analysis and a multinational registry.
    Krakoff LR; Sartori S
    Blood Press Monit; 2016 Apr; 21(2):128-30. PubMed ID: 26544525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example.
    Bulsei J; Darlington M; Durand-Zaleski I; Azizi M;
    Blood Press; 2018 Apr; 27(2):66-72. PubMed ID: 29069927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
    Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
    Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
    [TBL] [Abstract][Full Text] [Related]  

  • 60. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
    Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.